30 closest matches · ranked by relevance
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Adult Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 0; 0.15; 0 proportion of participants
Brain and Central Nervous System Tumors
Primary: Feasibility
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Desmoplastic/Nodular Medulloblastoma · Medulloblastoma · Medulloblastoma With Extensive Nodularity
Primary: Progression-free Survival (PFS) — 52.0 percent probability
Recurrent Childhood Medulloblastoma
Primary: Objective Response (CR+PR) Sustained for ≥ 8 Weeks — 1 participants
Central Nervous System Neoplasm · Pineoblastoma · Recurrent Medulloblastoma
Primary: Overall Survival — 2.43; 13.6 percent probability
Medulloblastoma
Primary: Event-free Survival (EFS) — 76.3; 84.9; 85.8; 85.8 probability of 3 year EFS
Anaplastic Medulloblastoma · Medulloblastoma · Supratentorial Embryonal Tumor, Not Otherwise Specified
Primary: Number of Patients Who Have Either a Complete Response (CR) Rate or No Complete Response Rate — 13; 15; 16; 15 Participants — p=0.35
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Metastatic Medulloblastoma · High Risk Supratentorial PNET · Metastatic PNET
Primary: Event-free Survival — 7 Participants
Medulloblastoma
Primary: Percentage of Participants With Overall Response Rate (ORR) According to Independent Review Committee (IRC) From Date First Participant Randomized, 13-Sep-2013 to Date…
Brain and Central Nervous System Tumors · Long-term Effects Secondary to Cancer Therapy in Children
Primary: Cumulative Incidence of Ototoxicity — 12; 16; 16; 15 percentage of participants
Medulloblastoma · Rhabdomyosarcoma · Neuroblastoma
Primary: Number of Participants With Dose-limiting Toxicities (DLT) in Phase I — 0; 1; 0; 0 participants
Glioblastoma · Malignant Glioma · Medulloblastoma Recurrent
Primary: Percentage of Patients for Whom 3 or More Vaccines Can be Made — 90.9 percentage of participants
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Anaplastic Ependymoma · Brain Ependymoma · Cellular Ependymoma
Primary: Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or…
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 9.33; 7.62 Months